Suspended NA INTERVENTIONAL 1-arm NCT04064879

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

Sponsor: Cell Surgical Network Inc.

Interventions AD-SVF

Updated 7 times since 2019 Last updated: Sep 26, 2022 Started: Aug 16, 2018 Primary completion: Aug 15, 2023 Completion: Aug 16, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Pending FDA approval

Listed as NCT04064879, this NA trial focuses on Chronic Migraine, Headache and remains suspended. Sponsored by Cell Surgical Network Inc., it has been updated 7 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Suspended NA
Jul 2024 — Sep 2024 [monthly]

Suspended NA
Sep 2022 — Jul 2024 [monthly]

Suspended NA
Apr 2021 — Sep 2022 [monthly]

Suspended NA
Jan 2021 — Apr 2021 [monthly]

Suspended NA

▶ Show 2 earlier versions

Jan 2020 — Jan 2021 [monthly]

Suspended NA
Sep 2019 — Jan 2020 [monthly]

Suspended NA

First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cell Surgical Network Inc.
Neurological Associates of West Los Angeles

Data source: Neurological Associates of West Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santa Monica, United States